Dr. Ippei Miyagawa, M.D., Ph.D., is an associate professor at the First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, in Kitakyushu. His research endeavors primarily focus on establishing precision medicine in highly heterogeneous systemic autoimmune diseases, specifically emphasizing psoriatic arthritis. Driven by this goal, he employs diverse methodologies to stratify patients and develop strategic treatment utilizing molecularly targeted drugs. Notably, his groundbreaking work includes the classification of PsA into four distinct subgroups based on peripheral blood immunophenotyping, with each subgroup demonstrating improved disease activity when treated with specific biologics. Additionally, Dr. Miyagawa’s findings highlight the value of serum IL-22 concentration as a biomarker for achieving Minimal Disease Activity with TNF-i and IL-17A-i. His contributions have been widely recognized and honored by numerous academic societies in Japan, APLAR, and EULAR, establishing him as a highly active and promising young rheumatologist in this field.